General Dynamics Corporation vs Revvity Inc — how do they compare? General Dynamics Corporation trades at $331.88 (market cap $89.26B), while Revvity Inc trades at $154.49 (market cap $16.98B). The key difference: General Dynamics Corporation is far larger — about 5.3× Revvity Inc's market cap, and General Dynamics Corporation pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Revvity Inc for 12 Days on average.
| GD | RVTY | |
|---|---|---|
Market Cap | $89.26B | $16.98B |
Volume | 1,496,273 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $395.97 | $157.36 |
52-Week Low | $312.53 | $82.26 |
Typical Hold Time | 85 Days | 12 Days |
Enterprise Value | $94.40B | $19.30B |
Dividend Yield | 1.93% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% amid bearish technical signals, though fundamentals remain solid with consistent earnings beats and strong defense contract visibility. The stock shows oversold RSI readings while maintaining healthy profitability metrics including 8.18% net margin and 17.8% ROE. Recent Pentagon spending focus and dividend stability support the investment case despite near-term price pressure.
GD presents a compelling value opportunity with 57% analyst buy ratings and $420.57 consensus target representing 29% upside. Defense budget tailwinds and submarine/vehicle demand provide growth catalysts, though technical weakness and defense sector volatility pose near-term risks. The company's consistent cash flow generation and dividend payments offer stability for long-term investors.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →